Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Editas Medicine (EDIT)

Editas Medicine (EDIT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,375,947
  • Shares Outstanding, K 51,303
  • Annual Sales, $ 31,940 K
  • Annual Income, $ -109,950 K
  • 60-Month Beta 2.65
  • Price/Sales 91.37
  • Price/Cash Flow N/A
  • Price/Book 6.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.35
  • Number of Estimates 5
  • High Estimate 0.69
  • Low Estimate -0.62
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +167.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.91 +3.51%
on 02/03/20
34.37 -21.97%
on 01/15/20
-5.69 (-17.50%)
since 01/14/20
3-Month
22.51 +19.15%
on 11/18/19
34.37 -21.97%
on 01/15/20
+4.16 (+18.36%)
since 11/14/19
52-Week
19.29 +39.04%
on 10/10/19
34.37 -21.97%
on 01/15/20
+6.96 (+35.05%)
since 02/14/19

Most Recent Stories

More News
Back from the Weekend and Back to New Highs

Back from the Weekend and Back to New Highs

SAVE : 43.88 (-1.57%)
DKS : 44.07 (-1.56%)
BBY : 90.21 (-0.21%)
ADNT : 27.65 (-0.65%)
AL : 45.29 (-0.02%)
MTW : 12.80 (-1.16%)
CAE : 30.54 (+0.79%)
OLED : 177.69 (-2.07%)
NTLA : 13.86 (-10.64%)
CRSP : 55.80 (-3.99%)
EDIT : 26.82 (-0.07%)
JenaValve Technology Closes $50 Million Financing

JenaValve Technology, Inc., developer and manufacturer of the JenaValve Pericardial Transcatheter Aortic Valve Replacement (TAVR) System for the treatment of aortic valve disease, announces that it has...

EDIT : 26.82 (-0.07%)
Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference

Provides updates on advancements in in vivo and engineered cell medicine programs

JPM : 137.46 (-0.30%)
EDIT : 26.82 (-0.07%)
Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Sandhill Therapeutics, Inc., a cellular immuno-oncology company, announced a strategic research collaboration, license, and option...

EDIT : 26.82 (-0.07%)
Editas Medicine Reports Inducement Grants to New Chief Financial Officer

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company's newly appointed Chief Financial Officer, Michelle Robertson. In connection...

EDIT : 26.82 (-0.07%)
Implied Volatility Surging for Editas (EDIT) Stock Options

Investors need to pay close attention to Editas (EDIT) stock based on the movements in the options market lately.

EDIT : 26.82 (-0.07%)
Editas Medicine Strengthens Executive Leadership Team to Support Long-term Growth

Michelle Robertson joins as Chief Financial Officer

EDIT : 26.82 (-0.07%)
Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101

Editas (EDIT) progresses well on developing its lead candidate EDIT-101 to treat LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a concern.

AGN : 198.32 (-0.47%)
BMY : 66.38 (+0.45%)
EDIT : 26.82 (-0.07%)
PRQR : 8.56 (+1.06%)
Interesting EDIT Put And Call Options For February 14th

Investors in Editas Medicine Inc saw new options become available today, for the February 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options chain...

EDIT : 26.82 (-0.07%)
Editas Medicine to Present at the 38th Annual J.P. Morgan Healthcare Conference

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 38th Annual J.P. Morgan...

JPM : 137.46 (-0.30%)
EDIT : 26.82 (-0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade EDIT with:

Business Summary

Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 27.44
1st Resistance Point 27.13
Last Price 26.82
1st Support Level 26.44
2nd Support Level 26.06

See More

52-Week High 34.37
Fibonacci 61.8% 28.61
Fibonacci 50% 26.83
Last Price 26.82
Fibonacci 38.2% 25.05
52-Week Low 19.29

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar